

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

11 Jun 2026

### The effect of oral melatonin in the treatment of acute respiratory distress syndrome in neonates

#### Protocol summary

##### Study aim

Investigating the effect of oral melatonin in the treatment of acute respiratory distress syndrome in infants

##### Design

The current study is a randomized, block-blocked, double-blind clinical trial that includes two control and intervention groups, in which 37 babies will be studied in each group, and finally, the data will be analyzed with spss 16 software. The phase of this study is 3, that is, it compares the results of treatment of people using new treatment and the results of treatment of people using standard treatment. The groups in this study are parallel and two groups are studied during a specific time.

##### Settings and conduct

Seventy four premature babies weighing less than 2500 grams or gestational age less than 37 weeks born in Imam Reza Hospital Mashhad were randomly divided into two groups, one group was given oral melatonin and standard treatment (surfactant therapy with respiratory support). and in the other group, only standard treatment will be done. The dose of melatonin is 10 mg/kg for three days, which is prescribed once a day.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria include: infants with RDS beyond the respiratory distress. Exclusion criteria include: neonatal sepsis (positive blood culture); respiratory diseases other than RDS (chest x-ray examination); cardiovascular diseases (pulse oximetry examination of the right hand and lower limbs) or diseases of the central nervous system; kidney failure.

##### Intervention groups

The intervention group will include infants who, in addition to the standard treatment, will be treated with oral melatonin at a dose of 10 mg/kg per day for three days. The control group will receive standard treatment (surfactant therapy and respiratory support).

##### Main outcome variables

The oxidant test, C-reactive protein test (CRP

)respiratory distress score of the newborn; the number of surfactant doses are investigated.

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20130308012743N3**

Registration date: **2022-11-13, 1401/08/22**

Registration timing: **registered\_while\_recruiting**

Last update: **2022-11-13, 1401/08/22**

Update count: **0**

##### Registration date

2022-11-13, 1401/08/22

##### Registrant information

##### Name

Ezat Khodashenas

##### Name of organization / entity

Mashhad University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 51 1727 3943

##### Email address

khodashenase@mums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2022-08-23, 1401/06/01

##### Expected recruitment end date

2023-08-23, 1402/06/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

**Trial completion date**  
empty

**Scientific title**  
The effect of oral melatonin in the treatment of acute respiratory distress syndrome in neonates

**Public title**  
oral melatonin in the treatment of acute respiratory distress syndrome

**Purpose**  
Treatment

**Inclusion/Exclusion criteria**  
**Inclusion criteria:**  
Infants with respiratory distress syndrome with any grade of respiratory distress  
**Exclusion criteria:**  
Neonatal sepsis Neonates with Respiratory distress disease other than RSD Neonates with cardiovascular diseases or diseases of the central nervous system  
Neonates with kidney failure

**Age**  
From **1 day** old to **30 days** old

**Gender**  
Both

**Phase**  
3

**Groups that have been masked**

- Participant
- Outcome assessor

**Sample size**  
Target sample size: **74**

**Randomization (investigator's opinion)**  
Randomized

**Randomization description**  
The allocation of infants will be done using block methods. A random sequence will be generated using four blocks of sealed envelope.com. The envelopes will be printed by the researcher after randomization and will be placed inside the envelopes and the envelope lids will be closed. Envelopes are numbered in random order. Then, we first explain the purpose of the study to the person and he / she will sign the informed consent and receive the intervention based on the envelope number and the order specified in it.

**Blinding (investigator's opinion)**  
Double blinded

**Blinding description**  
In this double-blind study, two groups of people under study, who are infants, and the outcome evaluator were blinded to the way the study was conducted.

**Placebo**  
Not used

**Assignment**  
Parallel

**Other design features**

**Secondary Ids**  
empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics Connate of Mashhad University of Medical Sciences

##### Street address

Qureshi Bul, Daneshgah Ave, Mashhad, Iran

##### City

Mashhad

##### Province

Razavi Khorasan

##### Postal code

9137913316

#### Approval date

2022-05-17, 1401/02/27

#### Ethics committee reference number

IR.MUMS.MEDICAL.REC.1401.154

## Health conditions studied

### 1

#### Description of health condition studied

Distress syndrome of neonates

#### ICD-10 code

P22.0

#### ICD-10 code description

P22.0Respiratory distress syndrome of newborn

## Primary outcomes

### 1

#### Description

Pro-antioxidant

#### Timepoint

Laboratory examination is done on the first and third day of birth.

#### Method of measurement

By measuring pro-antioxidant test

### 2

#### Description

C-reactive protein factor (CRP)

#### Timepoint

Laboratory examination is done on the first and third day of birth.

#### Method of measurement

By measuring CRP

### 3

#### Description

respiratory distress score

#### Timepoint

Laboratory examination is done on the first and third day of birth.

#### Method of measurement

By Measuring Respiratory distress score

## Secondary outcomes

empty

## Intervention groups

1

### Description

Intervention group: The intervention group will include infants who, in addition to the standard treatment, will be treated with oral melatonin at a dose of 10 mg/kg per day for three days.

### Category

Treatment - Drugs

2

### Description

Control group: They will undergo standard treatment (surfactant therapy and respiratory support).

### Category

Treatment - Drugs

## Recruitment centers

1

### Recruitment center

#### Name of recruitment center

Imam Reza Hospital

#### Full name of responsible person

Farnaz Mousavi

#### Street address

Ibn Sina Ave, Imam Reza Hospital , Mashhad , Iran

#### City

Mashhad

#### Province

Razavi Khorasan

#### Postal code

9137916616

#### Phone

+98 51 3852 1121

#### Email

dr.farnazmousavi@gmail.com

## Sponsors / Funding sources

1

### Sponsor

#### Name of organization / entity

Mashhad University of Medical Sciences

#### Full name of responsible person

Majid Ghayour Mobarhan

#### Street address

Qoreshi Bul, Daneshgah Ave, Mashhad, Iran

#### City

Mashhad

#### Province

Razavi Khorasan

#### Postal code

9137913316

#### Phone

+98 51 3852 1121

#### Email

ghayourm@mums.ac.ir

### Grant name

### Grant code / Reference number

### Is the source of funding the same sponsor organization/entity?

Yes

### Title of funding source

Mashhad University of Medical Sciences

### Proportion provided by this source

100

### Public or private sector

Public

### Domestic or foreign origin

Domestic

### Category of foreign source of funding

empty

### Country of origin

### Type of organization providing the funding

Academic

## Person responsible for general inquiries

### Contact

#### Name of organization / entity

Mashhad University of Medical Sciences

#### Full name of responsible person

Farnaz Mousavi

#### Position

Fellowship of neonatology

#### Latest degree

Subspecialist

#### Other areas of specialty/work

Pediatrics

#### Street address

Imam Reza Hospital, Ibn Sina Ave, Mashhad, Iran

#### City

Mashhad

#### Province

Razavi Khorasan

#### Postal code

9137913316

#### Phone

+98 51 3852 1121

#### Email

dr.farnazmousavi@gmail.com

## Person responsible for scientific inquiries

### Contact

#### Name of organization / entity

Mashhad University of Medical Sciences

#### Full name of responsible person

Farnaz mousavi

#### Position

fellowship of neonatology

dr.darnazmousavi@gmail.com

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Pediatrics

**Street address**

Imam Reza Hospital, Ibn Sina Ave

**City**

Mashhad

**Province**

Razavi Khorasan

**Postal code**

9137913316

**Phone**

+98 51 3852 1121

**Email**

dr.farnazmousavi@gmail.com

**Person responsible for updating data**

**Contact**

**Name of organization / entity**

Mashhad University of Medical Sciences

**Full name of responsible person**

Farnaz Mousavi

**Position**

neonatology

**Latest degree**

Specialist

**Other areas of specialty/work**

Pediatrics

**Street address**

Imam Reza Hospital , Ibn Sina Ave, Mashhad , Iran

**City**

Mashhad

**Province**

Razavi Khorasan

**Postal code**

91379133169

**Phone**

+98 51 3852 1121

**Fax**

**Email**

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available

**Title and more details about the data/document**

All data can be shared after patients are made unidentified

**When the data will become available and for how long**

data can be accessible 6 months after results are published

**To whom data/document is available**

Data can be accessible through an email to the corresponding author

**Under which criteria data/document could be used**

data will be available for researchers in universities and other scientific institution

**From where data/document is obtainable**

After sending a request email to the corresponding author data will be sent in 1 month

**What processes are involved for a request to access data/document**

Carrying out analysis on data is permitted

**Comments**